Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy for cancer patients. Co.'s lead product candidate, RP1, is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF. Co. has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4. Co. has designed its RP3 product candidate to express immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-). The REPL stock yearly return is shown above.
The yearly return on the REPL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the REPL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|